Literature DB >> 15511760

A randomised placebo controlled trial of loop diuretics in moderate/severe pre-eclampsia, following delivery.

G Matthews1, R Gornall, N J Saunders.   

Abstract

Nineteen patients with pre-eclampsia were randomised to receive 40 mg of frusemide or placebo by mouth daily for 7 days in the first post-partum week. Outcome measures included mean and maximum blood pressure, the need for additional antihypertensive treatment during that period and mean length of hospital stay. There were no statistically significant differences in outcome between the treatment and placebo groups although there was a trend to more rapid lowering of blood pressure following delivery in those receiving frusemide.

Entities:  

Year:  1997        PMID: 15511760     DOI: 10.1080/01443619750114040

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  4 in total

Review 1.  Blood pressure-lowering efficacy of loop diuretics for primary hypertension.

Authors:  Vijaya M Musini; Pouria Rezapour; James M Wright; Ken Bassett; Ciprian D Jauca
Journal:  Cochrane Database Syst Rev       Date:  2015-05-22

2.  Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial.

Authors:  Joana Lopes Perdigao; Jennifer Lewey; Adi Hirshberg; Nathanael Koelper; Sindhu K Srinivas; Michal A Elovitz; Lisa D Levine
Journal:  Hypertension       Date:  2021-02-08       Impact factor: 10.190

Review 3.  Postpartum management of hypertensive disorders of pregnancy: a systematic review.

Authors:  Alexandra E Cairns; Louise Pealing; James M N Duffy; Nia Roberts; Katherine L Tucker; Paul Leeson; Lucy H MacKillop; Richard J McManus
Journal:  BMJ Open       Date:  2017-11-28       Impact factor: 2.692

4.  Diuretics vs. placebo for postpartum blood pressure control in preeclampsia (DIUPRE): a randomized clinical trial.

Authors:  Telma Cursino; Leila Katz; Isabela Coutinho; Melania Amorim
Journal:  Reprod Health       Date:  2015-08-05       Impact factor: 3.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.